非奈利酮治疗非糖尿病肾病82例疗效分析OA

Objective To study the efficacy and safety of the non-steroidal mineralocorticoid receptor antagonist,finerenone,in the treatment of patients with non-diabetic kidney disease(NDKD).Methods A retrospective analysis was conducted on the clinical data of 82 patients with NDKD collected from the Department of Nephrology at Sichuan Provincial People's Hospital between January 2023 and November 2024.All patients received finerenone therapy while maintaining their basic treatment regimen.The primary outcome index was the rate of change in urinary protein at 1,3,and 6 months of treatment,defined as[(follow-up value-baseline value)/baseline value]× 100％.Results In the subgroup with 24-hour urine protein quantification(24 h UTP),the reductions in 24 h UTP at 1,3,and 6 months of treatment were 21.5％(Z=-4.113,P＜0.001),30.7％(Z=-3.285,P=0.001),and 43.3％(Z=-3.000,P=0.003),respectively.In the urinary albumin-to-creatinine ratio(UACR)subgroup,UACR decreased by 25.1％from baseline at 1 month(Z=-2.853,P=0.004),but changes at 3 and 6 months did not reach statistical significance(P＞0.05 for both).Overall tolerability was good during follow-up.Among 82 patients,1 case of hyperkalemia,one case of hypotension,and one case of elevated transaminases occurred.No other serious adverse events were observed.Conclusion Finerenone demonstrates significant effects in lowering urine protein and favorable safety in patients with NDKD,potentially offering additional renal protection for this patient population.